1 – 10 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
- Contribution to journal › Article
-
Mark
ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell-dependent tumor immunity and synergizes with PD-1 blockade
(2025) In Cancer immunology research
- Contribution to journal › Article
-
Mark
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer : Biomarkers associated with outcomes from OPTIMIZE-1
(2025) In Cell Reports Medicine
- Contribution to journal › Article
-
Mark
Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform
- Contribution to journal › Article
- 2024
-
Mark
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes
- Contribution to journal › Article
-
Mark
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1) : a single-arm, multicentre phase 1b/2 study
- Contribution to journal › Article
-
Mark
Next-generation CD40 agonists for cancer immunotherapy
- Contribution to journal › Scientific review
- 2023
-
Mark
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
- Contribution to journal › Article
-
Mark
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
- Contribution to journal › Article
-
Mark
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
- Contribution to journal › Article
